23.41 USD
-0.02 (-0.09%)
23.5049 USD
+0.09 (+0.41%)
CPRX gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. CPRX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. An interesting combination arises when we look at growth and value: CPRX is growing strongly while it also seems undervalued. These ratings could make CPRX a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year CPRX was profitable.
In the past year CPRX had a positive cash flow from operations.
CPRX had positive earnings in each of the past 5 years.
In the past 5 years CPRX always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 20.69%, CPRX belongs to the best of the industry, outperforming 97.00% of the companies in the same industry.
CPRX has a Return On Equity of 23.65%. This is amongst the best in the industry. CPRX outperforms 96.63% of its industry peers.
Looking at the Return On Invested Capital, with a value of 21.23%, CPRX belongs to the top of the industry, outperforming 97.75% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for CPRX is in line with the industry average of 18.83%.
The 3 year average ROIC (20.37%) for CPRX is below the current ROIC(21.23%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROIC | 21.23% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
1.3 Margins
The Profit Margin of CPRX (37.64%) is better than 96.82% of its industry peers.
CPRX's Profit Margin has been stable in the last couple of years.
The Operating Margin of CPRX (44.78%) is better than 99.44% of its industry peers.
CPRX's Operating Margin has improved in the last couple of years.
CPRX has a Gross Margin of 85.68%. This is amongst the best in the industry. CPRX outperforms 87.83% of its industry peers.
CPRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% |
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CPRX is creating value.
Compared to 1 year ago, CPRX has more shares outstanding
The number of shares outstanding for CPRX has been increased compared to 5 years ago.
CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 15.93 indicates that CPRX is not in any danger for bankruptcy at the moment.
CPRX's Altman-Z score of 15.93 is amongst the best of the industry. CPRX outperforms 87.27% of its industry peers.
CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 15.93 |
ROIC/WACC2.45
WACC8.66%
2.3 Liquidity
A Current Ratio of 6.62 indicates that CPRX has no problem at all paying its short term obligations.
CPRX has a better Current ratio (6.62) than 68.73% of its industry peers.
CPRX has a Quick Ratio of 6.40. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
CPRX has a Quick ratio of 6.40. This is in the better half of the industry: CPRX outperforms 67.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 45.76% over the past year.
The Earnings Per Share has been growing by 34.29% on average over the past years. This is a very strong growth
The Revenue has grown by 25.56% in the past year. This is a very strong growth!
CPRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 36.89% yearly.
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
3.2 Future
CPRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.80% yearly.
CPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.21% yearly.
EPS Next Y13.52%
EPS Next 2Y14.64%
EPS Next 3Y10.93%
EPS Next 5Y26.8%
Revenue Next Year16.1%
Revenue Next 2Y12.2%
Revenue Next 3Y11.06%
Revenue Next 5Y11.21%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 13.61 indicates a correct valuation of CPRX.
Based on the Price/Earnings ratio, CPRX is valued cheaper than 96.07% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.31, CPRX is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 13.60, the valuation of CPRX can be described as correct.
Based on the Price/Forward Earnings ratio, CPRX is valued cheaper than 96.63% of the companies in the same industry.
CPRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.56, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.61 | ||
| Fwd PE | 13.6 |
4.2 Price Multiples
CPRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CPRX is cheaper than 98.13% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CPRX is valued cheaper than 97.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.26 | ||
| EV/EBITDA | 7.37 |
4.3 Compensation for Growth
CPRX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
CPRX has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.01
PEG (5Y)0.4
EPS Next 2Y14.64%
EPS Next 3Y10.93%
5. Dividend
5.1 Amount
No dividends for CPRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CPRX (11/28/2025, 8:21:28 PM)
After market: 23.5049 +0.09 (+0.41%)23.41
-0.02 (-0.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners85.12%
Inst Owner Change1.43%
Ins Owners5.59%
Ins Owner Change0.86%
Market Cap2.88B
Revenue(TTM)578.20M
Net Income(TTM)217.63M
Analysts88.57
Price Target35.19 (50.32%)
Short Float %6.93%
Short Ratio5.47
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.08%
Min EPS beat(2)4.13%
Max EPS beat(2)24.03%
EPS beat(4)4
Avg EPS beat(4)21.33%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)8
Avg EPS beat(8)18.46%
EPS beat(12)11
Avg EPS beat(12)14.56%
EPS beat(16)13
Avg EPS beat(16)9.74%
Revenue beat(2)2
Avg Revenue beat(2)4.27%
Min Revenue beat(2)2.19%
Max Revenue beat(2)6.34%
Revenue beat(4)4
Avg Revenue beat(4)4.39%
Min Revenue beat(4)2.19%
Max Revenue beat(4)6.34%
Revenue beat(8)7
Avg Revenue beat(8)3.51%
Revenue beat(12)11
Avg Revenue beat(12)3.34%
Revenue beat(16)13
Avg Revenue beat(16)2.97%
PT rev (1m)1.47%
PT rev (3m)1.47%
EPS NQ rev (1m)6.62%
EPS NQ rev (3m)11.54%
EPS NY rev (1m)0%
EPS NY rev (3m)0.14%
Revenue NQ rev (1m)3.08%
Revenue NQ rev (3m)3.31%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.61 | ||
| Fwd PE | 13.6 | ||
| P/S | 4.98 | ||
| P/FCF | 12.26 | ||
| P/OCF | 12.26 | ||
| P/B | 3.13 | ||
| P/tB | 3.63 | ||
| EV/EBITDA | 7.37 |
EPS(TTM)1.72
EY7.35%
EPS(NY)1.72
Fwd EY7.35%
FCF(TTM)1.91
FCFY8.16%
OCF(TTM)1.91
OCFY8.16%
SpS4.7
BVpS7.49
TBVpS6.44
PEG (NY)1.01
PEG (5Y)0.4
Graham Number17.02
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROCE | 28.06% | ||
| ROIC | 21.23% | ||
| ROICexc | 84.1% | ||
| ROICexgc | 187.79% | ||
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% | ||
| FCFM | 40.59% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
ROICexc(3y)162.63%
ROICexc(5y)159.51%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.92%
ROCE(5y)25.99%
ROICexgc growth 3Y8.72%
ROICexgc growth 5YN/A
ROICexc growth 3Y-30.16%
ROICexc growth 5YN/A
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 0.31% | ||
| Cap/Sales | 0.02% | ||
| Interest Coverage | 593.88 | ||
| Cash Conversion | 79.12% | ||
| Profit Quality | 107.83% | ||
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 | ||
| Altman-Z | 15.93 |
F-Score6
WACC8.66%
ROIC/WACC2.45
Cap/Depr(3y)0.72%
Cap/Depr(5y)100.44%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)162.12%
Profit Quality(5y)139.35%
High Growth Momentum
Growth
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
EPS Next Y13.52%
EPS Next 2Y14.64%
EPS Next 3Y10.93%
EPS Next 5Y26.8%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
Revenue Next Year16.1%
Revenue Next 2Y12.2%
Revenue Next 3Y11.06%
Revenue Next 5Y11.21%
EBIT growth 1Y48.97%
EBIT growth 3Y55%
EBIT growth 5Y43.74%
EBIT Next Year63.54%
EBIT Next 3Y23.99%
EBIT Next 5YN/A
FCF growth 1Y83.47%
FCF growth 3Y59.11%
FCF growth 5Y47.22%
OCF growth 1Y83.42%
OCF growth 3Y58.35%
OCF growth 5Y47.28%
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a fundamental rating of 8 / 10 to CPRX.
What is the valuation status of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a valuation rating of 7 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.
Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?
CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 9 / 10.
What is the financial health of CATALYST PHARMACEUTICALS INC (CPRX) stock?
The financial health rating of CATALYST PHARMACEUTICALS INC (CPRX) is 8 / 10.